The Latest Breaking News from Oncology

My oncologist has one of those little motivational prints hanging on his waiting room wall, with the simple statement, “Trust Your Instincts”. One day, bored with the long purgatory of the waiting room, I tweet this news to the world with the observation: “If I trusted my instincts, I’d run…

The U.S. Food and Drug Administration (FDA) has cleared the Eledon Pharmaceuticals’ (NASDAQ:ELDN) Investigational New Drug (IND) application to evaluate Tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant. Eledon shares traded in a range of $2.89 to $3.16 on a day volume of 31.27 thousand…

Lung, breast, and colorectal cancer patients across the North East will have their consultations in specific hospitals to maintain "equitable access" to treatment

Increased health awareness and the rapidly aging population are expected to drive the growth of healthcare companies. Healthcare stocks Cigna Corp. (CI), Humana (HUM), and McKesson Corp. (MCK) have bucked the market downtrend and are in momentum. Since the market is expected to remain under pressure in the near term,…

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ALX Oncology Holdings’ (NASDAQ: ALXO) Evorpacept for the treatment of patients with acute myeloid leukemia (AML).

Sarah McCann is a lead advanced nurse practitioner for active oncology at Glasgow's Beatson West of Scotland Cancer Centre, dedicating her life to treating cancer patients.

Much-loved matriarch Faith Dingle, played by Sally Dexter, will attend an oncology appointment after having her scan - but it's not good news on Emmerdale

invoX Pharma, a wholly-owned subsidiary of Sino Biopharmaceutical Limited, has agreed to acquire F-star Therapeutics Inc (NASDAQ:FSTX) for $7.12 per share.  The proposed acquisition values F-star at approximately $161 million.  Just a year ago, F-star priced its IPO at $7. F-star's next-generation tetravalent (2+2) bispecific antibody platform complements Sino Biopharma's existing capabilities and reinforces its global…

Ikena Oncology, Inc. (NASDAQ: IKNA) received Fast Track designation from the U.S. Food and Drug Administration (FDA) for IK-930, in patients with unresectable NF2-deficient malignant pleural mesothelioma (MPM).